Enzo Biochem, Inc. (ENZ)
NYSE: ENZ · IEX Real-Time Price · USD
+0.030 (2.65%)
Jun 14, 2024, 4:00 PM EDT - Market closed

Enzo Biochem Statistics

Total Valuation

Enzo Biochem has a market cap or net worth of $59.42 million. The enterprise value is $9.52 million.

Market Cap 59.42M
Enterprise Value 9.52M

Important Dates

The last earnings date was Thursday, June 13, 2024, after market close.

Earnings Date Jun 13, 2024
Ex-Dividend Date n/a

Share Statistics

Enzo Biochem has 51.23 million shares outstanding. The number of shares has increased by 3.71% in one year.

Shares Outstanding 51.23M
Shares Change (YoY) +3.71%
Shares Change (QoQ) +1.43%
Owned by Insiders (%) 24.08%
Owned by Institutions (%) 37.35%
Float 39.52M

Valuation Ratios

The trailing PE ratio is 1.26.

PE Ratio 1.26
Forward PE n/a
PS Ratio 12.59
Forward PS n/a
PB Ratio 0.86
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 0.21
EV / Sales 2.02
EV / EBITDA 0.21
EV / EBIT 0.22
EV / FCF n/a

Financial Position

The company has a current ratio of 3.50, with a Debt / Equity ratio of 0.11.

Current Ratio 3.50
Quick Ratio 2.82
Debt / Equity 0.11
Debt / EBITDA 0.16
Debt / FCF n/a
Interest Coverage -31.44

Financial Efficiency

Return on equity (ROE) is 61.20% and return on invested capital (ROIC) is 5.37%.

Return on Equity (ROE) 61.20%
Return on Assets (ROA) 42.50%
Return on Capital (ROIC) 5.37%
Revenue Per Employee $26,374
Profits Per Employee $249,905
Employee Count 179
Asset Turnover 0.05
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -39.90% in the last 52 weeks. The beta is 0.78, so Enzo Biochem's price volatility has been lower than the market average.

Beta (1Y) 0.78
52-Week Price Change -39.90%
50-Day Moving Average 1.12
200-Day Moving Average 1.28
Relative Strength Index (RSI) 52.43
Average Volume (30 Days) 107,357

Short Selling Information

The latest short interest is 603,572, so 1.18% of the outstanding shares have been sold short.

Short Interest 603,572
Short Previous Month 729,226
Short % of Shares Out 1.18%
Short % of Float 1.53%
Short Ratio (days to cover) 5.38

Income Statement

In the last 12 months, Enzo Biochem had revenue of $4.72 million and earned $44.73 million in profits. Earnings per share was $0.92.

Revenue 4.72M
Gross Profit 16.48M
Operating Income 4.10M
Pretax Income 44.73M
Net Income 44.73M
EBIT 43.35M
Earnings Per Share (EPS) $0.92
Full Income Statement

Balance Sheet

The company has $57.16 million in cash and $7.26 million in debt, giving a net cash position of $49.90 million or $0.97 per share.

Cash & Cash Equivalents 57.16M
Total Debt 7.26M
Net Cash 49.90M
Net Cash Per Share $0.97
Equity / Book Value 69.03M
Book Value Per Share 1.35
Working Capital 54.07M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$42.21 million and capital expenditures -$995,000, giving a free cash flow of -$43.20 million.

Operating Cash Flow -42.21M
Capital Expenditures -995,000
Free Cash Flow -43.20M
FCF Per Share -$0.84
Full Cash Flow Statement


Gross margin is 348.99%, with operating and profit margins of 86.78% and 947.53%.

Gross Margin 348.99%
Operating Margin 86.78%
Pretax Margin 947.53%
Profit Margin 947.53%
EBITDA Margin 949.67%
EBIT Margin 918.32%
FCF Margin -915.06%

Dividends & Yields

Enzo Biochem does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.71%
Shareholder Yield -3.71%
Earnings Yield 75.28%
FCF Yield -72.70%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a

Stock Splits

The last stock split was on October 21, 2004. It was a forward split with a ratio of 105:100.

Last Split Date Oct 21, 2004
Split Type Forward
Split Ratio 105:100


Enzo Biochem has an Altman Z-Score of -0.48 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -0.48
Piotroski F-Score 6